RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours from nets results Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Yao presents the results of his study which has shown that the mTOR inhibitor, everolimus, can delay tumour growth among both gastrointestinal and lung NETs, at a press conference at ECC 2015.nnThe results of this phase III study have shown that the mTOR inhibitor everolimus can delay tumour growth among patients with both advanced, progressive, non-functional gastrointestinal (GI) and lung neuroendocrine tumours (NETs).nnAround 75% of NETS are non-functional meaning that they do not produc
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)